Trial Radar AI
De klinische studie NCT05182970 (MIMET) voor Prediabetes, Acuut myocardinfarct, Niet-ST-elevatie myocardinfarct, ST-Elevatie Myocardinfarct is recruterend. Bekijk de kaartweergave van de Klinische Studies Radar en de AI-ontdekkingstools voor alle details. Of stel hier een vraag.
Eén studie komt overeen met de filtercriteria
Kaartweergave
Terug naar zoekresultaten

Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET)

Recruterend
Informatie over klinische studies is voornamelijk in het Engels beschikbaar. Trial Radar AI kan echter helpen! Klik op 'Leg studie uit' om de informatie over de studie te bekijken en te bespreken in de taal van uw keuze.
De klinische studie NCT05182970 (MIMET) onderzoekt preventie bij Prediabetes, Acuut myocardinfarct, Niet-ST-elevatie myocardinfarct, ST-Elevatie Myocardinfarct. Deze Fase 3 interventioneel-studie heeft de status recruterend. Het doel is om 5.160 deelnemers te includeren vanaf 2 december 2021. De studie wordt geleid door Karolinska Instituut en de voltooiing is gepland op 1 mei 2026. Laatste update op ClinicalTrials.gov: 2 april 2024.
Beknopte samenvatting
Prediabetes is associated to an increased risk of cardiovascular disease and mortality. Although metformin can delay progression to diabetes there is a lack of RCTs evaluating the effect of metformin on cardiovascular outcomes. MIMET aims to investigate if addition of metformin to standard care has effects on the occurrence of cardiovascular events after acute myocardial infarction in patients with newly detected prediabetes (identified by oral glucose tolerance test, HbA1c or fasting glucose levels).
Uitgebreide beschrijving
The study is a national multicenter R-RCT associated to the The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART registry) where participants, after informed consent, will be randomly assigned to either open treatment with standard care + metformin or standard care alone in a 1:1 ratio. Standard care consists of diet and life-style advice according to national guidelines but does not include metformin. Baseline data for individual patients will be collected from the SWEDEHEART registry. Patients will be followed per routine care at 2 and 12 months post index AMI and in addition at a final study visit at 24 months. Laboratory measurements and collection of SAE will be performed yearly. In total n=5150 patients is expected to be followed for major CV event (all-cause mortality, myocardial infarction, heart failure and stroke) by linkage with SWEDEHEART and national health registries.
Officiële titel

The Myocardial Infarction and New Treatment With Metformin Study (MIMET) - a R-RCT to Study Metformin and the Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Newly Detected Prediabetes

Aandoeningen
PrediabetesAcuut myocardinfarctNiet-ST-elevatie myocardinfarctST-Elevatie Myocardinfarct
Publicaties
Wetenschappelijke artikelen en onderzoekspapers gepubliceerd over deze klinische studie:
Andere studie-ID's
  • MIMET
  • 2019-05382
NCT-ID
NCT05182970
Startdatum (Werkelijk)
2021-12-02
Laatste update geplaatst
2024-04-02
Verwachte einddatum
2026-05
Inschrijving (Geschat)
5.160
Studietype
Interventioneel
FASE
Fase 3
Status
Recruterend
Primaire doel
Preventie
Toewijzing
Gerandomiseerd
Interventiemodel
Parallel
Blindering
Geen (Open-label)
Armen / Interventies
Deelnemersgroep/StudiearmInterventie/Behandeling
Actieve comparatorMetformin on top of standard care
Metformin will be prescribed by the Investigator at the study site and dispensed at pharmacy of choice by the patient. Metformin will be recommended to be gradually titrated to minimize gastrointestinal side effects with a start dose of 500 mg 1x1 for 1 week and thereafter 500 mg 1x2 with an individualised target dose of 2000 mg daily depending on tolerability. The goal is to a have minimal dose of 500 mg 1x2. Patients will be informed to stop medication in events of sever nausea, vomiting or dehydration according to standard practice. The threshold for metformin titration or adding another drug during follow-up is recommended to be assessed individually by the Investigator at the study site, responsible for the patient. Patients with eGFR \<60 cannot be included in the MIMET study. If GFR is between 30-45 ml/min during the study, metformin should be reduced to 1000 mg daily. Metformin is contraindicated if GFR \<30 ml/min. Standard care will be the same as in the control arm.
Metformine
Individualised target dose of 2000 mg daily depending on tolerability.
Geen interventieStandard care alone
Standard care according to national guidelines. In Sweden there is no pharmacological intervention recommended for individuals with prediabetes at present. Standard care includes diet and life-style advice, which will be given to both groups in the same manner according to local routines, based on the present guidelines. Secondary preventive treatment includes physical activity, participating in exercise program, dietary habits, BMI and or waist circumference, smoking and EQ-5D will be followed in accordance with the routinely reported SWEDEHEART-SEPHIA variables.
N.v.t.
Primaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Time to major CV event
Major CV event; a composite endpoint of first of all-cause death or main diagnosis of MI, heart failure or stroke (reported in SWEDEHEART, the National Patient Register and the Cause of Death Register).
Estimated follow-up for each patient is 1-4 years
Secundaire uitkomst
UitkomstmaatBeschrijving van de uitkomstmaatTijdsbestek
Time to the composite endpoint CV death, main diagnosis of MI, heart failure or stroke.
Time to first event included in the composite endpoint CV death, main diagnosis of MI, heart failure or stroke.
Estimated follow-up for each patient is 1-4 years
Time to the composite endpoint of all-cause death, main diagnosis of MI, stroke and revascularisation (CABG or PCI >4 months after the index AMI).
Time to first event included in the composite endpoint of all-cause death, main diagnosis of MI, stroke and revascularisation (CABG or PCI \>4 months after the index AMI).
Estimated follow-up for each patient is 1-4 years
All-cause death
Time to all-cause death
Estimated follow-up for each patient is 1-4 years
CV death
Time to CV death
Estimated follow-up for each patient is 1-4 years
Hospitalisation with MI
Time to readmission for MI. Hospital admission for MI during day 0-30 after index AMI will be excluded
Estimated follow-up for each patient is 1-4 years
Hospitalisation with stroke
Time to hospitalisation for stroke (main diagnosis)
Estimated follow-up for each patient is 1-4 years
Hospitalisation with heart failure
Time to hospitalisation for heart failure (main diagnosis)
Estimated follow-up for each patient is 1-4 years
New cancer diagnosis
Time to new cancer diagnosis defined as the first occurrence of any cancer in the National Patient Register
Estimated follow-up for each patient is 1-4 years
Initiation of any glucose lowering therapy
Time to initiation of any glucose lowering therapy (ATC code A10 in the Prescribed Drug Register, excluding randomisation to metformin)
Estimated follow-up for each patient is 1-4 years
Diabetes diagnosis
Defined as diabetes diagnosis in National Patient Register and/or prescribed glucose lowering treatment in the Prescribed Drug Register excluding randomisation to metformin in the active treatment arm
Estimated follow-up for each patient is 1-4 years
Geschiktheidscriteria

Leeftijd van deelnemers
Volwassene, Oudere volwassene
Minimumleeftijd
18 Years
Geslachten die in aanmerking komen voor de studie
Allen

I. AMI

II. Swedish citizens with a personal ID number ≥18 years and ≤80 years

III. Newly diagnosed prediabetes:

  1. HbA1c 42-47 mmol/mol or
  2. Capillary or venous fasting plasma glucose concentration 6.1-6.9 mmol/L or
  3. 2-hour post-load capillary glucose concentration 8.9-12.1 mmol/L or
  4. 2-h post-load venous plasma glucose concentration 7.8-11.0 mmol/L
  5. HbA1c <48 mmol/mol and 2-hour post-load capillary glucose concentration >12.1 mmol/L or 2-h post-load venous plasma glucose concentration >11.0 mmol/L (thus elevated 2-hour glucose levels in the diabetes range but without HbA1c levels diagnostic for diabetes)

IV. Naïve to metformin and other glucose lowering therapy

V. Signed informed consent

I. Type 1 diabetes

II. Known type 2 diabetes

III. Indication for glucose lowering treatment

IV. Acute condition with high risk for volume depletion, circulatory shock, hypoxia

V. Serious illness, other than cardiovascular, with short life expectancy

VI. Renal failure (eGFR <60ml/min)

VII. Hepatic failure

VIII. Malignancy within the last year

IX. Contraindication or hypersensitivity to the study drug

X. Alcohol or drug abuse

XI. Pregnancy or breastfeeding

XII. Women of childbearing potential without adequate anticonception during any part of the study period

XIII. Previous hospitalisation for lactic acidosis

XIV. Predicted inability to comply with the study protocol

Karolinska Institutet logoKarolinska Instituut
Verantwoordelijke instantie
Anna Norhammar, Hoofdonderzoeker, Professor, Karolinska Institutet
Centraal Contactpersoon
Contact: Anna Norhammar, MD, Prof., +46858701568, [email protected]
Contact: Viveca Ritsinger, MD, PhD, +46372585000, [email protected]
1 Studielocaties in 1 landen
Medicinkliniken, Ljungby Hospital, Ljungby, 341 35, Sweden
Thomas Aronsson, Head of Clinic, Contact
Viveca Ritsinger, MD PhD, Hoofdonderzoeker
Recruterend